Pharmaceutical Processing World

HHS gives Vaxxas $22M to support vaccine patch tech

By |

Vaxxas micropatch vaccine COVID-19 High Density Microarray Patch HD-MAP

Vaxxas’ patch comes in a hockey-puck-shaped applicator with a foil seal. [Image courtesy of Vaxxas]

Vaxxas announced today that it has received a $22 million award from the Biomedical Advanced Research and Development Authority (BARDA) at U.S. HHS to support a clinical study involving the company’s vaccine-delivery patch.

The money will mostly pay for a Phase 1 clinical study in which Vaxxas’ high-density micro-array patch (HD-MAP) delivering pandemic influenza vaccine to more than 400 people. Researchers chose pandemic influenza vaccine for the $24.1 million study in order to comprehensively baseline the immune responses and safety of the novel HD-MAP vaccination platform.

Vaxxas (Cambridge, Mass.; Brisbane, Australia) is also actively investigating opportunities to improve the performance of other pandemic vaccines including against COVID-19, as well as a broad range of non-pandemic infectious disease vaccines.

Get the full story on our sister site Drug Delivery Business News. 

About The Author

Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at cnewmarker@wtwhmedia.com.

Tell Us What You Think!

Related Articles Read More >

Search Pharmaceutical Processing World